MA50675A - Inhibiteurs de la creb binding protein (cbp) - Google Patents
Inhibiteurs de la creb binding protein (cbp)Info
- Publication number
- MA50675A MA50675A MA050675A MA50675A MA50675A MA 50675 A MA50675 A MA 50675A MA 050675 A MA050675 A MA 050675A MA 50675 A MA50675 A MA 50675A MA 50675 A MA50675 A MA 50675A
- Authority
- MA
- Morocco
- Prior art keywords
- cbp
- inhibitors
- binding protein
- creb binding
- creb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (fr) | 2017-09-15 | 2018-09-14 | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| PCT/US2018/051235 WO2019055877A1 (fr) | 2017-09-15 | 2018-09-14 | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| PCT/US2019/039936 WO2020006483A1 (fr) | 2018-06-29 | 2019-06-28 | Inhibition de la protéine de liaison à creb (cbp) |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA50675A true MA50675A (fr) | 2021-04-07 |
| MA50675B1 MA50675B1 (fr) | 2021-09-30 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA50675A MA50675B1 (fr) | 2018-06-29 | 2019-07-01 | Inhibiteurs de la creb binding protein (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (fr) |
| EP (1) | EP3998266A1 (fr) |
| JP (4) | JP6781806B2 (fr) |
| KR (2) | KR102805503B1 (fr) |
| CN (2) | CN112513038B (fr) |
| AU (3) | AU2019295790B2 (fr) |
| BR (1) | BR112020026783A2 (fr) |
| CA (1) | CA3105099A1 (fr) |
| CY (1) | CY1124762T1 (fr) |
| DK (1) | DK3587418T3 (fr) |
| ES (1) | ES2900105T3 (fr) |
| HR (1) | HRP20211698T1 (fr) |
| HU (1) | HUE056885T2 (fr) |
| IL (3) | IL279734B2 (fr) |
| LT (1) | LT3587418T (fr) |
| MA (1) | MA50675B1 (fr) |
| MX (2) | MX2020014303A (fr) |
| PL (1) | PL3587418T3 (fr) |
| PT (1) | PT3587418T (fr) |
| RS (1) | RS62732B1 (fr) |
| SA (1) | SA520420909B1 (fr) |
| SG (1) | SG11202012767UA (fr) |
| SI (1) | SI3587418T1 (fr) |
| SM (1) | SMT202100636T1 (fr) |
| WO (1) | WO2020006483A1 (fr) |
| ZA (2) | ZA202100509B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279734B2 (en) * | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
| TW202102494A (zh) | 2019-03-15 | 2021-01-16 | 美商弗瑪治療公司 | 抑制環amp-反應元件-結合蛋白(creb) |
| CN113784967B (zh) * | 2019-03-15 | 2024-07-26 | 福马治疗股份有限公司 | 用于治疗雄激素受体阳性形式的癌症的组合物和方法 |
| AU2021298154A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| EP4171556A1 (fr) | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | Combinaison d'un inhibiteur de bromodomaine cbp/p300 et d'un inhibiteur d'egfr pour une utilisation dans le traitement de nsclc mutant egfr |
| US11795168B2 (en) * | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
| WO2026090300A1 (fr) * | 2024-10-23 | 2026-04-30 | Foghorn Therapeutics Inc. | Composés et leurs utilisations |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (fr) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Inhibiteurs de la signalisation cellulaire |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| EP1339812B1 (fr) | 2000-11-20 | 2008-07-16 | MERCK PATENT GmbH | Composes photoisomerisables chiraux |
| CA2463136A1 (fr) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Modulateurs de ship 1 |
| WO2003045929A1 (fr) | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (fr) | 2003-11-13 | 2008-10-06 | ||
| WO2005066162A1 (fr) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon |
| JP4790703B2 (ja) | 2004-04-07 | 2011-10-12 | 武田薬品工業株式会社 | 環式化合物 |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| AU2007249827A1 (en) | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| EP1878724A1 (fr) | 2006-07-15 | 2008-01-16 | sanofi-aventis | Synthèse régiosélective des benzimidazoles et azabenzimidazoles catalysée par le palladium |
| CA2574531C (fr) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Promoteurs de l'acetylation d'hat et utilisations de compositions contenant ceux-ci pour promouvoir l'immunogenicite |
| WO2008157680A2 (fr) | 2007-06-21 | 2008-12-24 | The Wistar Institute | Procédés et compositions servant à moduler l'activité de la p300/cbp |
| WO2009000413A1 (fr) | 2007-06-26 | 2008-12-31 | Sanofi-Aventis | Synthèse régiosélective catalysée par le cuivre de benzimidazoles et d'azabenzimidazoles |
| JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | 11β−HSD1阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| WO2010110380A1 (fr) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | Composé de pipéridine condensé et agent pharmaceutique le contenant |
| WO2010118208A1 (fr) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Dérivés benzoxazepin-4-(5h)-yle et leur utilisation pour traiter le cancer |
| AU2010237633B2 (en) | 2009-04-15 | 2015-09-17 | Jw Pharmaceutical Corporation | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| WO2010138490A1 (fr) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazèpines comme inhibiteurs de mtor et méthodes d'utilisation et de fabrication |
| MX2011012584A (es) | 2009-05-26 | 2012-02-21 | Exelixis Inc | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CA2791738C (fr) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Composes d'aryl imidazolyl destines au traitement du cancer |
| WO2011150156A2 (fr) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Composés hétéroarylés et leurs procédés d'utilisation |
| WO2012019093A1 (fr) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Composés synthétiques et procédés pour diminuer l'auto-administration de nicotine |
| EP2651405A2 (fr) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Inhibiteurs de caséine kinase 1 (ck1 ) |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (fr) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | Inhibiteurs de p300/cbp et leurs méthodes d'utilisation |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| WO2014045305A1 (fr) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Composés tricycliques condensés substitués, compositions et applications médicales correspondantes |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| BR122019007990B1 (pt) | 2013-11-18 | 2021-05-04 | Forma Therapeutics, Inc | Composto, e, composição farmacêutica |
| RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
| CN107073125A (zh) | 2014-09-19 | 2017-08-18 | 基因泰克公司 | Cbp/ep300和bet抑制剂用于治疗癌症的用途 |
| EP3632915A1 (fr) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300 |
| US10435402B2 (en) | 2015-01-08 | 2019-10-08 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (fr) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Composés bicycliques, compositions et applications médicinales correspondantes |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| CN109414596B (zh) | 2016-05-12 | 2023-09-29 | 密歇根大学董事会 | Ash1l抑制剂和用其进行治疗的方法 |
| WO2017205536A2 (fr) | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Composés thérapeutiques et leurs utilisations |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| WO2019055877A1 (fr) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 |
| IL279734B2 (en) * | 2018-06-29 | 2024-11-01 | Forma Therapeutics Inc | Inhibiting creb binding protein (cbp) |
-
2019
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/fr not_active Ceased
- 2019-06-28 CA CA3105099A patent/CA3105099A1/fr active Pending
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 IL IL313466A patent/IL313466B2/en unknown
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/fr active Pending
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| IL281962A (en) | Il-12 heterodimeric fc-fusion proteins | |
| EP3932338C0 (fr) | Tourniquet | |
| LT3587418T (lt) | Creb surišančio baltymo (cbp) inhibitoriai | |
| EP3630783A4 (fr) | Inhibiteurs protéiques de liaison à la pénicilline | |
| EP3630782A4 (fr) | Inhibiteurs de protéines de liaison à la pénicilline | |
| EP3621994A4 (fr) | Protéines de liaison à la mésothéline | |
| MA54543A (fr) | Inhibiteurs de kif18a | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP3833350A4 (fr) | Inhibiteurs de pyrrolopyrimidine itk | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| IL284664A (en) | Multispecific binding proteins | |
| EP3802551A4 (fr) | Inhibiteurs de protéine de liaison à la pénicilline | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3938358A4 (fr) | Inhibiteurs de rad51 | |
| EP3661961A4 (fr) | Anticorps se liant à l'alpha-synucléine active | |
| DK3737402T5 (da) | Modificeret protein | |
| IL284317A (en) | Pseudofab-based multispecific binding proteins | |
| EP3555092A4 (fr) | Inhibiteurs de protéine kinase | |
| EP3765265A4 (fr) | Agent liant | |
| MA51611A (fr) | Inhibiteurs de pi4kiiibêta | |
| EP3792200A4 (fr) | Conteneur-citerne |